Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?
Clerico M, De Mercanti SF, Signori A, Iudicello M, Cordioli C, Signoriello E, Lus G, Bonavita S, Lavorgna L, Maniscalco GT, Curti E, Lorefice L, Cocco E, Nociti V, Mirabella M, Baroncini D, Mataluni G, Landi D, Petruzzo M, Lanzillo R, Gandoglia I, Laroni A, Frangiamore R, Sartori A, Cavalla P, Costantini G, Sormani MP, Capra R. Clerico M, et al. Among authors: maniscalco gt. Neurotherapeutics. 2020 Jan;17(1):200-207. doi: 10.1007/s13311-019-00776-7. Neurotherapeutics. 2020. PMID: 31452081 Free PMC article.
Uric acid in relapsing-remitting multiple sclerosis: a 2-year longitudinal study.
Moccia M, Lanzillo R, Costabile T, Russo C, Carotenuto A, Sasso G, Postiglione E, De Luca Picione C, Vastola M, Maniscalco GT, Palladino R, Brescia Morra V. Moccia M, et al. Among authors: maniscalco gt. J Neurol. 2015;262(4):961-7. doi: 10.1007/s00415-015-7666-y. Epub 2015 Feb 12. J Neurol. 2015. PMID: 25673130
Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression.
Moccia M, Lanzillo R, Palladino R, Chang KC, Costabile T, Russo C, De Rosa A, Carotenuto A, Saccà F, Maniscalco GT, Brescia Morra V. Moccia M, et al. Among authors: maniscalco gt. Mult Scler. 2016 Apr;22(5):659-67. doi: 10.1177/1352458515599075. Epub 2015 Sep 11. Mult Scler. 2016. PMID: 26362896
No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study).
Lanzillo R, Quarantelli M, Pozzilli C, Trojano M, Amato MP, Marrosu MG, Francia A, Florio C, Orefice G, Tedeschi G, Bellantonio P, Annunziata P, Grimaldi LM, Comerci M, Brunetti A, Bonavita V, Alfano B, Marini S, Brescia Morra V; ARIANNA study group. Lanzillo R, et al. Mult Scler. 2016 Aug;22(9):1163-73. doi: 10.1177/1352458515611222. Epub 2015 Oct 14. Mult Scler. 2016. PMID: 26466947 Clinical Trial.
Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study.
Lugaresi A, De Robertis F, Clerico M, Brescia Morra V, Centonze D, Borghesan S, Maniscalco GT; RIVER study group. Lugaresi A, et al. Among authors: maniscalco gt. Expert Opin Drug Deliv. 2016 Jul;13(7):931-5. doi: 10.1517/17425247.2016.1148029. Epub 2016 Feb 24. Expert Opin Drug Deliv. 2016. PMID: 26909646
Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity.
Patti F, Messina S, Solaro C, Amato MP, Bergamaschi R, Bonavita S, Bruno Bossio R, Brescia Morra V, Costantino GF, Cavalla P, Centonze D, Comi G, Cottone S, Danni M, Francia A, Gajofatto A, Gasperini C, Ghezzi A, Iudice A, Lus G, Maniscalco GT, Marrosu MG, Matta M, Mirabella M, Montanari E, Pozzilli C, Rovaris M, Sessa E, Spitaleri D, Trojano M, Valentino P, Zappia M; SA.FE. study group. Patti F, et al. Among authors: maniscalco gt. J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):944-51. doi: 10.1136/jnnp-2015-312591. Epub 2016 May 9. J Neurol Neurosurg Psychiatry. 2016. PMID: 27160523 Free PMC article.
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study).
Messina S, Solaro C, Righini I, Bergamaschi R, Bonavita S, Bossio RB, Brescia Morra V, Costantino G, Cavalla P, Centonze D, Comi G, Cottone S, Danni MC, Francia A, Gajofatto A, Gasperini C, Zaffaroni M, Petrucci L, Signoriello E, Maniscalco GT, Spinicci G, Matta M, Mirabella M, Pedà G, Castelli L, Rovaris M, Sessa E, Spitaleri D, Paolicelli D, Granata A, Zappia M, Patti F; SA.FE. study group. Messina S, et al. Among authors: maniscalco gt. PLoS One. 2017 Aug 1;12(8):e0180651. doi: 10.1371/journal.pone.0180651. eCollection 2017. PLoS One. 2017. PMID: 28763462 Free PMC article.
Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study.
Laroni A, Signori A, Maniscalco GT, Lanzillo R, Russo CV, Binello E, Lo Fermo S, Repice A, Annovazzi P, Bonavita S, Clerico M, Baroncini D, Prosperini L, La Gioia S, Rossi S, Cocco E, Frau J, Torri Clerici V, Signoriello E, Sartori A, Zarbo IR, Rasia S, Cordioli C, Cerqua R, Di Sapio A, Lavorgna L, Pontecorvo S, Barrilà C, Saccà F, Frigeni B, Esposito S, Ippolito D, Gallo F, Sormani MP; iMUST group. Laroni A, et al. Among authors: maniscalco gt. Neurology. 2017 Nov 28;89(22):2222-2229. doi: 10.1212/WNL.0000000000004686. Epub 2017 Nov 1. Neurology. 2017. PMID: 29093064 Free article.
125 results